Immunotherapy followed by targeted therapy has emerged as the new standard of care for patients with melanoma with BRAF V600 mutations.
Back
DREAMSeq Trial Clarifies Optimal Sequencing in BRAF V600–Mutant Melanoma
Andrew L. Pecora, MD, discusses the phase 3 DREAMseq trial (NCT02224781), which showed that nivolumab (Opdivo) plus ipilimumab (Yervoy) should be administered prior to the combination of a BRAF and MEK inhibitor in patients with advanced BRAF-mutant melanoma.
DREAMSeq Trial Clarifies Optimal Sequencing in BRAF V600–Mutant Melanoma
Episodes
All
All
Andrew L. Pecora, MD, discusses the key efficacy findings from the phase 3 DREAMSEQ trial in BRAF-mutated melanoma.
Findings from the DREAMseq trial indicate that nivolumab plus ipilimumab should be administered prior to the combination of a BRAF and MEK inhibitor in patients with advanced BRAF-mutant melanoma.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings
2
Dr Tarantino on the Evolution of TROP2-Directed ADCs in First-Line TNBC
3
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
4
Dr Hurvitz on Updated PFS Data From the SERENA-6 Trial in Breast Cancer
5